US 5635517A
· Muller et al.
· 1997
[cited by applicant]
US 6306663B1
· Kenten et al.
· 2001
[cited by applicant]
US 7041298B2
· Deshaies et al.
· 2006
[cited by applicant]
US 7208157B2
· Deshaies et al.
· 2007
[cited by applicant]
US 20150119435A1
· Crews et al.
· 2015
[cited by applicant]
US 20150291562A1
· Crew et al.
· 2015
[cited by applicant]
US 20160022642A1
· Crews et al.
· 2016
[cited by applicant]
US 20160058872A1
· Crew et al.
· 2016
[cited by applicant]
US 20170008904A1
· Crew et al.
· 2017
[cited by applicant]
US 20170037004A1
· Crew et al.
· 2017
[cited by applicant]
US 20180085465A1
· Bradner et al.
· 2018
[cited by applicant]
WO WO2002059106A1
· 2002
[cited by applicant]
WO WO2008027542A2
· 2008
[cited by applicant]
WO WO2008033567A1
· 2008
[cited by applicant]
WO WO2008039489A2
· 2008
[cited by applicant]
WO WO2008115516A2
· 2008
[cited by applicant]
WO WO2009042177A1
· 2009
[cited by applicant]
WO WO2009139880A1
· 2009
[cited by applicant]
WO WO2009145899A1
· 2009
[cited by applicant]
WO WO2010053732A1
· 2010
[cited by applicant]
WO WO2010107485A1
· 2010
[cited by applicant]
WO WO2013106646A2
· 2013
[cited by applicant]
WO WO2013124026A1
· 2013
[cited by applicant]
WO WO2013170147A1
· 2013
[cited by applicant]
WO WO2016065139A1
· 2016
[cited by applicant]
WO WO2016105518A1
· 2016
[cited by applicant]
WO WO2016146985A1
· 2016
[cited by applicant]
WO WO2016169989A1
· 2016
[cited by applicant]
WO WO2016191178A1
· 2016
[cited by applicant]
WO WO2016197032A1
· 2016
[cited by applicant]
WO WO2016197114A1
· 2016
[cited by applicant]
WO WO2017007612A1
· 2017
[cited by applicant]
WO WO2017024317A2
· 2017
[cited by applicant]
WO WO2017024318A1
· 2017
[cited by applicant]
WO WO2017024319A1
· 2017
[cited by applicant]
WO WO2017079267A1
· 2017
[cited by applicant]
WO WO2017161119A1
· 2017
[cited by applicant]
WO WO2017176708A1
· 2017
[cited by applicant]
WO WO2017176957A1
· 2017
[cited by applicant]
WO WO2017176958A1
· 2017
[cited by applicant]
WO WO2017180417A1
· 2017
[cited by applicant]
WO WO2017201069A1
· 2017
[cited by applicant]
WO WO2017201449A1
· 2017
[cited by applicant]
WO WO2018051107A1
· 2018
[cited by applicant]
WO WO2018052945A1
· 2018
[cited by applicant]
WO WO2018052949A1
· 2018
[cited by applicant]
WO WO2018053354A1
· 2018
[cited by applicant]
WO WO2018071606A1
· 2018
[cited by applicant]
WO WO2018085247A1
· 2018
[cited by applicant]
WO WO2018102067A2
· 2018
[cited by applicant]
WO WO2018102725A1
· 2018
[cited by applicant]
WO WO2018118598A1
· 2018
[cited by applicant]
WO WO2018118947A1
· 2018
[cited by applicant]
WO WO2018119357A1
· 2018
[cited by applicant]
WO WO2018119441A1
· 2018
[cited by applicant]
WO WO2018119448A1
· 2018
[cited by applicant]
WO WO2018140809A1
· 2018
[cited by applicant]
WO WO2018144649A1
· 2018
[cited by applicant]
WO WO2018169777A1
· 2018
[cited by applicant]
WO WO2018189554A1
· 2018
[cited by applicant]
WO WO2019032632A1
· 2019
[cited by applicant]
Registry Entry for 908105-74-8 published Sep. 21, 2016. (Year: 2016).
[cited by examiner]
Registry Entry for 1394538-03-4 published Jan. 6, 2014 (Year: 2014).
[cited by examiner]
Registry Entry for 1413479-09-0 published Dec. 11, 2012. (Year: 2012).
[cited by examiner]
U.S. Pat. No. 10,646,575 B2, U.S. Appl. No. 16/186,339, Philips et al., May 12, 2020.
[cited by applicant]
U.S. Pat. No. 10,660,968 B2, U.S. Appl. No. 16/186,334, Philips et al., May 26, 2020.
[cited by applicant]
U.S. Pat. No. 10,849,982 B2, U.S. Appl. No. 16/186,341, Phillips et al., Dec. 1, 2020.
[cited by applicant]
U.S. Pat. No. 10,905,768 B2, U.S. Appl. No. 16/872,225, Phillips et al., Feb. 2, 2021.
[cited by applicant]
U.S. Pat. No. 11,185,592 B2, U.S. Appl. No. 16/882,236, Phillips et al., Nov. 30, 2021.
[cited by applicant]
U.S. Pat. No. 11,254,672 B2, U.S. Appl. No. 16/809,325, Norcross et al., Feb. 22, 2022.
[cited by applicant]
U.S. Pat. No. 11,401,256 B2, U.S. Appl. No. 16/809,345, Norcross et al., Aug. 2, 2022.
[cited by applicant]
U.S. Pat. No. 11,407,732 B2, U.S. Appl. No. 17/498,617, Henderson et al., Aug. 9, 2022.
[cited by applicant]
U.S. Pat. No. 11,459,335 A1, U.S. Appl. No. 16/721,650, Phillips et al., Oct. 4, 2022.
[cited by applicant]
U.S. Pat. No. 11,524,949 A1, U.S. Appl. No. 16/874,475, Phillips et al., Dec. 13, 2022.
[cited by applicant]
U.S. Pat. No. 11,584,748 A1, U.S. Appl. No. 17/072,896, Nasveschuk et al., Feb. 21, 2023.
[cited by applicant]
U.S. Pat. No. 11,623,929 A1, U.S. Appl. No. 17/103,621, Nasveschuk et al., Apr. 11, 2023.
[cited by applicant]
U.S. Pat. No. 11,673,902 B2, U.S. Appl. No. 17/843,769, Nasveschuk et al., Jun. 13, 2023.
[cited by applicant]
U.S. Pat. No. 11,691,972 A1, U.S. Appl. No. 17/541,035, Nasveschuk et al., Jul. 4, 2023.
[cited by applicant]
U.S. Pat. No. 11,753,397 A1, U.S. Appl. No. 17/031,550, Henderson et al., Sep. 12, 2023.
[cited by applicant]
U.S. Pat. No. 11,787,802 A1, U.S. Appl. No. 17/576,582, Norcross et al., Oct. 17, 2023.
[cited by applicant]
U.S. Pat. No. 11,802,131 A1, U.S. Appl. No. 16/809,336, Norcross et al., Oct. 31, 2023.
[cited by applicant]
US 2020/0308171 A1, U.S. Appl. No. 16/903,237, Jaeschke et al., Oct. 1, 2020.
[cited by applicant]
US 2021/0198256 A1, U.S. Appl. No. 17/192,634, Nasveschuk et al., Jul. 1, 2021.
[cited by applicant]
US 2022/0313826 A1, U.S. Appl. No. 17/107,781, Phillips et al., Oct. 6, 2022.
[cited by applicant]
US 2022/0313827 A1, U.S. Appl. No. 17/121,389, Phillips et al., Oct. 6, 2022.
[cited by applicant]
US 2022/0372016 A1, U.S. Appl. No. 17/351,935, Phillips et al., Nov. 24, 2022.
[cited by applicant]
US 2023/0014124 A1, U.S. Appl. No. 17/164,446, Phillips et al., Jan. 19, 2023.
[cited by applicant]
US 2023/0019060 A1, U.S. Appl. No. 17/465,583, Nasveschuk et al., Jan. 19, 2023.
[cited by applicant]
US 2023/0060334 A1, U.S. Appl. No. 17/901,775, Nasveschuk et al., Mar. 2, 2023.
[cited by applicant]
US 2023/0082430 A1, U.S. Appl. No. 17/723,199, Henderson et al., Mar. 16, 2023.
[cited by applicant]
US 2023/0095223 A1, U.S. Appl. No. 17/524,558, Phillips et al., Mar. 30, 2023.
[cited by applicant]
US 2023/0145336 A1, U.S. Appl. No. 18/084,380, Nasveschuk et al., May 11, 2023.
[cited by applicant]
US 2023/0190760 A1, U.S. Appl. No. 18/106,893, Proia et al., Jun. 22, 2023.
[cited by applicant]
US 2023/0192643 A1, U.S. Appl. No. 17/878,753, Norcross et al., Jun. 22, 2023.
[cited by applicant]
UA 2023/0233692 A1, U.S. Appl. No. 18/105,735, Henderson et al., Jul. 27, 2023.
[cited by applicant]
US 2023/0279023 A1, U.S. Appl. No. 17/959,144, Phillips et al., Sep. 7, 2023.
[cited by applicant]
US 2023/0339902 A1, U.S. Appl. No. 18/134,985, Nasveschuk et al., Oct. 26, 2023.
[cited by applicant]
US 2023/0357180 A1, U.S. Appl. No. 18/079,815, Phillips et al., Nov. 9, 2023.
[cited by applicant]
U.S. Appl. No. 18/240,231, Henderson et al., filed Aug. 30, 2023.
[cited by applicant]
U.S. Appl. No. 18/100,992, Nasveschuk et al., filed Jan. 24, 2023.
[cited by applicant]
U.S. Appl. No. 18/144,800, Nasveschuk et al., filed May 8, 2023.
[cited by applicant]
U.S. Appl. No. 18/134,971, Nasveschuk et al., filed Apr. 14, 2023.
[cited by applicant]
U.S. Appl. No. 18/134,990, Nasveschuk et al., filed Apr. 14, 2023.
[cited by applicant]
U.S. Appl. No. 17/965,199, Nasveschuk et al., filed Oct. 13, 2022.
[cited by applicant]
U.S. Appl. No. 18/370,186, Norcross et al., filed Sep. 19, 2023.
[cited by applicant]
U.S. Appl. No. 18/385,277, Norcross et al., filed Oct. 30, 2023.
[cited by applicant]
Bartlett, et al. “The evolution of thalidomide and its IMiD derivatives as anticancer agents.” Nat Rev Cancer 2004, 4(4):312-322.
[cited by applicant]
Berndsen et al. “New insights into ubiquitin E3 ligase mechanism” Nat. Struct. Mol. Biol. 2014, 21:301-307.
[cited by applicant]
Bondeson et al. “Catalytic in vivo protein knockdown by small-molecule PROTACs” Nature Chemical Biology 2015, 11:611-617.
[cited by applicant]
Buckley et al. “HaloPROTACS: Use of Small Molecule PROTACS to Induce Degradation of HaloTag Fusion Proteins” ACS Chemical Biology 2015, 10:1831-1837.
[cited by applicant]
Buckley et al. “Small-Molecule Control of Intracellular Protein Levels through Modulation of the Ubiquitin Proteasome System” Angewandte Reviews, 2014, 53:2312-2330.
[cited by applicant]
Burkhard et al. “Synthesis and Stability of Oxetane Analogs of Thalidomide and Lenalidomide” Organic Letters 2013, 15(17):4312-4315.
[cited by applicant]
C4 Therapeutics Presentation Patel—“Diverse Utility of Targeted Protein Degradation at C4 Therapeutics,” ChemBio, 1 page, Sep. 17, 2017.
[cited by applicant]
C4 Therapeutics Presentation Patel—“Advances in the Medicinal Chemistry of Targeted Protein Degradation,” 24 pages, Sep. 27, 2018.
[cited by applicant]
C4 Therapeutics Presentation Phillips—“Targeted Protein Degradation,” A new class of small-molecule drugs; applied pharmaceutical chemistry, Cambridge, MA, Apr. 5, 2018; 38 pages.
[cited by applicant]
C4 Therapeutics Presentation Phillips—“Small Molecule Driven Targeted Protein Degradation”, ChemBio in the Hub 47, Cambridge, MA, 47 pages (Oct. 22, 2018).
[cited by applicant]
C4 Therapeutics Presentation Chrissy Henderson, “Development of AchillesTAG degradation systems and their application to control CAR-T activity,” ChemBio in the Hub, Watertown, MA 1 page (Oct. 22, 2018).
[cited by applicant]
C4 Therapeutics Presentation Austin Elam, et al.—“Application of Biophysical Techniques to the Targeted Protein Degradation Therapeutic Strategy” Gibbs BioChem, Cambridge, MA), 1 page, Sep. 24, 2017.
[cited by applicant]
C4 Therapeutics Presentation Fisher—“Targeted Protein Degradation”, Targeted Protein Degradation Summit, Boston, MA, 39 pages, Oct. 24-25, 2018.
[cited by applicant]
Chamberlain et al. “Structure of the human cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs” Nature Structural and Molecule Biology, 2014, 21(9):803-809.
[cited by applicant]
Chang, X. and Stewart, K. A. “What is the functional role of the thalidomide binding protein cereblon?” Int J Biochem Mol Bio. 2011, 2(3):287-294.
[cited by applicant]
Contino-Pepin, et al., “Preliminary biological evaluations of new thalidomide analogues for multiple sclerosis application”, Bioorganic & Medicinal Chemistry Letters, 2009, 19(3), 878-881.
[cited by applicant]
Corson et al. “Design and applications of bifunctional small molecules: Why two heads are better than one” ACS Chemical Biology 2008, 3(11): 677-692.
[cited by applicant]
Crews, C. M. “Targeting the undruggable proteome: the small molecules of my dreams” Chemistry and Biology 2010, 17(6):551-555.
[cited by applicant]
Deshaies et al. “Ring domain E3 ubiquitin ligases.” Ann. Rev. Biochem. 2009, 78:399-434.
[cited by applicant]
Faden et al. “Generic tools for conditionally altering protein abundance and phenotypes on domain” Biol. Chem. 2014, 395(7-8):737-762.
[cited by applicant]
Fischer et al. “Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide” Nature 2014, 512:49-53.
[cited by applicant]
Fischer et al. “The Molecular Basis of CRL4DDB2/CSA Ubiquitin Ligase Architecture, Targeting, and Activation,” Cell 2011, 147:1024-1039.
[cited by applicant]
Gosink et al. “Redirecting the Specificity of Ubiquitination by Modifying Ubiquitin-Conjugating Enzymes” Proc. Natl. Acad. Sci. USA 1995, 92:9117-9121.
[cited by applicant]
International Application No. PCT/US19/35223, filed Jun. 3, 2019; International Search Report and Written Opinion dated Oct. 31, 2019, 10 pages.
[cited by applicant]
Ito et al., “Identification of a Primary Target of thalidomide teratogenicity”, Science, 2010, 327(5971), 1345-1350, XP0055062167.
[cited by applicant]
Itoh et al. “Protein knockdown using methyl bestatin-ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins” Journal of the American C…
[cited by applicant]
Jacques et al. “Differentiation of anti-inflammatory and antitumorigenic properties of stabilized enantiomers of thalidomide analogs” PNAS 2015, 112:E1471-E1479.
[cited by applicant]
Kronke et al. “Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells” Science 2014, 343(6168):301-305.
[cited by applicant]
Kronke et al. “Lenalidomide induces ubiquitination and degradation of CDK1 [alpha] in del(5q) MDS” Nature 2015, 523(7559):183-188.
[cited by applicant]
Lai et al. “Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL” Angewandte Chemie International Edition 2016, 55:807-810.
[cited by applicant]
Lee et al. “Targeted Degradation of the Aryl Hydrocarbon Receptor by the PROTAC Approach: A Useful Chemical Genetic Tool” ChemBioChem 2007, 8:2058-2062.
[cited by applicant]
Liu et al. “Design and biological characterization of hybrid compounds of curcumin and thalidomide for multiple myeloma” Organic and Biomolecular Chemistry 2013, 11:4757.
[cited by applicant]
Lu et al. “Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4” Chemistry and Biology 2015, 22(6):755-763.
[cited by applicant]
Lu et al. “The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins” Science 2014, 343:305-309.
[cited by applicant]
Nawaz et al. “Proteasome-Dependent Degradation of the Human Estrogen Receptor” Proc. Natl. Acad. Sci. USA 1999, 96:1858-1862.
[cited by applicant]
Neklesa et al. “Small-molecule hydrophobic tagging-induced degradation of HaloTag fusion proteins.” Nat Chem Biol 2011, 7(8):538-543.
[cited by applicant]
Prevet et al. “Microwave-assisted synthesis of functionalized spirohydantoins as 3-D privileged fragments for scouting the chemical space,” Tetrahedron Letters, May 18, 2016, vol. 57, pp. 2888-2894.
[cited by applicant]
Pubmed Compound Summary for CID 51072057, Tert-butyl 4-[9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4,4]nonan-7-yl]benzoate, U.S. National Library of Medicine, 3/ May 2011; pp. 1-17; p.…
[cited by applicant]
Pubmed Compound Summary for CID 45792656, '7-Cyclopropyl-1,3,7-triazaspiro[4,4]nonane-2m4-dione, U.S. National Library of Medicine, Jun. 21, 2010, pp. 1-13; (https://pubchem.ncbi.nlm.nih.gov/compound/45792656).
[cited by applicant]
Pubmed Compound Summary for CID 70731020, '7-(1,2,4)Triazolo[4,3-a]pyridine-3-y1)-2,7-diazaspiro[4,4]nonane-1,3-dione, U.S. National Library of Medicine, Mar. 4, 2013, pp. 1-11; (https://pubchem.ncbi.nlm.nih.gov/compoun…
[cited by applicant]
Raina et al. “Chemical Inducers of Targeted Protein Degradation” Journal of Biological Chemistry 2010, 285:11057-11060.
[cited by applicant]
Rodriguez-Gonzalez et al. “Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer” Oncogene 2008, 27:7201-7211.
[cited by applicant]
Ruchelman et al. “Isosteric analogs of lenalidomide and pomalidomide: Synthesis and biological activity” Bioorganic and Medicinal Chemistry Letters 2012, 23:360-365.
[cited by applicant]
Sakamoto et al. “Development of Protacs to Target Cancer-Promoting Proteins for Ubiquitination and Degradation” Molecular and Cellular Proteomics 2003, 2(12):1350-1357.
[cited by applicant]
Sakamoto et al. “Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation” PNAS 2001, 98(15):8554-8559.
[cited by applicant]
Schneekloth et al. “Chemical approaches to controlling intracellular protein degradation” Chembiochem 2005, 6(1):40-46.
[cited by applicant]
Schneekloth et al. “Chemical Genetic Control of Protein Levels: Selective in Vivo Targeted Degradation” Journal of the American Chemical Society 2004, 126(12):3748-3754.
[cited by applicant]
Schneekloth et al. “Targeted Intracellular Protein Degradation Induced by a Small Molecule: En Route to Chemical Proteomics” Bioorganic and Medicinal Chemistry Letters 2008, 18:5904-5908.
[cited by applicant]
Shoji, et al., “Modified DNA Aptamer That Binds the (R)-Isomer of a Thalidomide Derivative with High Enantioselectivity”, J. Am. Chem. Soc., 2007, 129, 1456-1464.
[cited by applicant]
Spratt et al. “RBR E3 ubiquitin ligases: new structures, new insights, new questions.” Biochem. 2014, 458:421-437.
[cited by applicant]
Toure et al. “Small-Molecule PROTACs: New Approaches to Protein Degradation” Angewandte Chemie International Edition 2016, 55:1966-1973.
[cited by applicant]
Wang et al. “Roles of F-box proteins in cancer.” Nat. Rev. Cancer 2014, 14:233-347.
[cited by applicant]
Winter et al. “Phthalimide conjugation as a strategy for in vivo target protein degradation” Science 2015, 348(6241):1376-1381.
[cited by applicant]
Zengerle et al. “Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4” ACS Chem. Biol. 2015, 10:1770-1777.
[cited by applicant]
Zhou et al. “Harnessing the Ubiquitination Machinery to Target the Degradation of Specific Cellular Proteins” Molecular Cell 2000, 6:751-756.
[cited by applicant]
Database Registry: RN 1413489-08-3, published Dec. 11, 2012.
[cited by applicant]
Database Registry: RN 141387-70-3, published Dec. 11, 2012.
[cited by applicant]
Database Registry: RN 1413479-09-0, published Dec. 11, 2012.
[cited by applicant]
U.S. Pat. No. 11,992,531 B2, U.S. Appl. No. 17/107,781, Philips et al., May 28, 2024.
[cited by applicant]
US 2023/0372496 A1, U.S. Appl. No. 18/134,971, Nasveschuk et al., Nov. 23, 2023.
[cited by applicant]
US 2023/0416251 A1, U.S. Appl. No. 18/100,992, Nasveschuk et al., Dec. 28, 2023.
[cited by applicant]
US 2024/0018118 A1, U.S. Appl. No. 18/134,990, Nasveschuk et al., Jan. 18, 2024.
[cited by applicant]
US 2024/0051953 A1, U.S. Appl. No. 17/965,569, Nasveschuk et al., Feb. 15, 2024.
[cited by applicant]
US 2024/0076300 A1, U.S. Appl. No. 18/144,800, Nasveschuk et al., Mar. 7, 2024.
[cited by applicant]
US 2024/0109889 A1, U.S. Appl. No. 18/370,186, Norcross et al., Apr. 4, 2024.
[cited by applicant]
US 2024/0158418 A1, U.S. Appl. No. 18/516,589, Nasveschuk et al., May 16, 2024.
[cited by applicant]
U.S. Appl. No. 18/534,395, Nasveschuk et al., filed Dec. 8, 2023.
[cited by applicant]
U.S. Appl. No. 18/600,097, Jackson et al., filed Mar. 8, 2024.
[cited by applicant]
U.S. Appl. No. 18/642,602, Phillips et al., filed Apr. 22, 2024.
[cited by applicant]